• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Respiratory/Inflammation
  • A comparison of Symbicort SMART (160/4.5µg) and Symbicort Turbuhaler 160/4.5 µg, plus terbutaline Turbuhaler 0.4 mg as needed, for treatment of asthma - a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients from 16 years

Disease
asthma
Drug Name
Symbicort
Generic Name
budesonide/formoterol
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
III
Start Date
Feb 16, 2009
Study Name
D589LC00001
Study Id
D589LC00001
Recruiting Status
Closed
Protocol Status
Not Available
Report
Jul 22, 2011
  • D589LC00001.pdf (576 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013